New PET tracer aims to spot hidden amyloid deposits
NCT ID NCT07232459
First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 2 times
Summary
This study is testing a new imaging agent called [18F]FT8 to see if it can help doctors better see and diagnose amyloidosis, a disease where abnormal proteins build up in organs like the heart. The study will involve 20 patients with amyloidosis and 5 healthy volunteers. Researchers will compare the new PET scan results with standard tests like echocardiograms and MRIs to check if it is safe and more accurate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 25 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2025
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Healthy volunteers and patients with confirmed or suspected systemic or cardiac amyloidosis, including cases secondary to hematologic disorders or genetic diseases.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
1. Subject Recruitment Participants will be recruited from outpatients and/or inpatient populations of the Hematology Department at Tianjin Medical University General Hospital. The principal investigator and collaborating hematologists will ensure consistent application of diagnosis and enrollment criteria based on standardized guidelines. The planned enrollment includes 20 patients with systemic amyloidosis (including cardiac involvement) and 5 healthy volunteers. 2. Amyloidosis Patients: 2.1 Inclusion Criteria: Subjects must meet all of the following criteria: 1. Adult patients (age ≥ 18 years); 2. Suspected, newly diagnosed, or previously diagnosed with cardiac amyloidosis, with supporting evidence from one or more of the following: cardiac MRI, contrast-enhanced CT, serum biomarkers (e.g., NT-proBNP, Troponin), or histopathological confirmation of amyloidosis. 3. Scheduled to undergo a clinical Pan-Amyloid PET/CT scan as part of standard care or clinical evaluation. 4. Able to understand the study procedures and provide written informed consent. 2.2 Exclusion Criteria Subjects will be excluded based on any of the following: 1. Confirmed non-cardiac amyloidosis or other non-amyloid cardiac pathologies that could confound image interpretation. 2. Pregnancy or breastfeeding. 3. Any medical, psychological, or social condition that, in the opinion of the investigator, would compromise the subject's ability to participate fully or complete the study follow-up. 3\. Healthy Volunteers: 3.1 Inclusion Criteria: Subjects must meet all of the following criteria: 1. Adult subjects (age ≥ 18 years); 2. No clinical evidence of active cardiac or systemic disease, as confirmed by medical history review, physical examination, and electrocardiogram (ECG). 3. Able to understand the study procedures and provide written informed consent. 3.2 Exclusion Criteria: Subjects will be excluded based on any of the following: 1. History or current diagnosis of any significant cardiac, hepatic, renal, or neurological disorder. 2. Pregnancy or breastfeeding. 3. Any condition that, in the opinion of the investigator, could pose an increased risk from the study procedure or interfere with the interpretation of study data.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amyloid are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Affiliated Hospital of Qingdao University
RECRUITINGQingdao, Shandong, 266000, China
-
The First Affiliated Hospital of University of Science and Technology of China
RECRUITINGHefei, Anhui, 230000, China
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, Tianjin Municipality, 350005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple reaching exercise strengthen ankles and cut injury risk?
- Banking blood and bone marrow to decode plasma cell disorders
- Urine chemistry may hold key to safer dosing for brain drug
- Could a skin patch replace IV sedation? early test in healthy adults
- Can a common amino acid help your body build more protein?
- Laser zaps skin amyloid deposits in rare itching disorder